Aadi Bioscience, Inc. (NASDAQ:AADI) Shares Sold by Strs Ohio

Strs Ohio decreased its stake in shares of Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) by 26.5% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,500 shares of the company’s stock after selling 900 shares during the period. Strs Ohio’s holdings in Aadi Bioscience were worth $35,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in AADI. Legal & General Group Plc acquired a new position in shares of Aadi Bioscience in the second quarter worth about $34,000. Cubist Systematic Strategies LLC raised its position in Aadi Bioscience by 21.1% during the second quarter. Cubist Systematic Strategies LLC now owns 15,538 shares of the company’s stock valued at $191,000 after acquiring an additional 2,712 shares in the last quarter. Point72 Asset Management L.P. raised its position in Aadi Bioscience by 156.2% during the second quarter. Point72 Asset Management L.P. now owns 542,044 shares of the company’s stock valued at $6,678,000 after acquiring an additional 330,513 shares in the last quarter. Renaissance Technologies LLC raised its position in Aadi Bioscience by 24.4% during the second quarter. Renaissance Technologies LLC now owns 173,522 shares of the company’s stock valued at $2,138,000 after acquiring an additional 34,000 shares in the last quarter. Finally, American International Group Inc. bought a new position in Aadi Bioscience during the second quarter valued at approximately $83,000. Institutional investors own 67.09% of the company’s stock.

Aadi Bioscience Price Performance

AADI opened at $12.80 on Monday. Aadi Bioscience, Inc. has a fifty-two week low of $11.00 and a fifty-two week high of $21.15. The firm’s fifty day moving average price is $12.89 and its two-hundred day moving average price is $13.05. The company has a market capitalization of $312.26 million, a P/E ratio of -4.30 and a beta of 1.26.

Aadi Bioscience (NASDAQ:AADIGet Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Aadi Bioscience had a negative return on equity of 44.28% and a negative net margin of 569.57%. The business had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $3.60 million. On average, equities research analysts expect that Aadi Bioscience, Inc. will post -2.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH dropped their price target on shares of Aadi Bioscience to $47.00 in a research report on Tuesday, November 15th.

Aadi Bioscience Company Profile

(Get Rating)

Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Featured Stories

Want to see what other hedge funds are holding AADI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating).

Institutional Ownership by Quarter for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.